The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1
Abstract
Inhibition of the protein kinase WEE1 synergizes with chemotherapy in preclinical models and WEE1 inhibitors are being explored as potential cancer therapies. Here, we investigate the mechanism that underlies this synergy. We show that WEE1 inhibition forces S-phase–arrested cells directly into mitosis without completing DNA synthesis, resulting in highly abnormal mitoses characterized by dispersed chromosomes and disorganized bipolar spindles, ultimately resulting in mitotic exit with gross micronuclei formation and apoptosis. This mechanism of cell death is shared by CHK1 inhibitors, and combined WEE1 and CHK1 inhibition forces mitotic entry from S-phase in the absence of chemotherapy. We show that p53/p21 inactivation combined with high expression of mitotic cyclins and EZH2 predispose to mitotic entry during S-phase with cells reliant on WEE1 to prevent premature cyclin-dependent kinase (CDK)1 activation. These features are characteristic of aggressive breast, and other, cancers for which WEE1 inhibitor combinations represent a promising targeted therapy. Significance: Here, we describe a novel mechanism of inducing cancer cell death by WEE1 inhibition, forcing mitotic entry directly from S-phase. This mechanism represents a potential therapeutic approach for aggressive breast cancers, and in particular triple-negative and basal-like breast cancers, as WEE1 inhibition specifically targets the features inherent in these cancers: frequent TP53 mutation and high expression of mitotic cyclins and the polycomb protein EZH2. Cancer Discov; 2(6); 524–39. © 2012 AACR. This article is highlighted in the In This Issue feature, p. 473
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Chou, T.-C. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.10 · Cited by 5,163
p21 is a universal inhibitor of cyclin kinases
Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., & Beach, D. (1993) · Nature · doi:10.1038/366701a0 · Cited by 3,368
Requirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803
Hendzel, M. J., Wei, Y., Mancini, M. A., Van Hooser, A., Ranalli, T., Brinkley, B. R., Bazett-Jones, D. P., & Allis, C. D. (1997) · Chromosoma · doi:10.1007/s004120050256 · Cited by 1,859
Kleer, C. G., Cao, Q., Varambally, S., Shen, R., Ota, I., Tomlins, S. A., Ghosh, D., Sewalt, R. G. A. B., Otte, A. P., Hayes, D. F., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1933744100 · Cited by 1,649
Sanchez, Y., Wong, C., Thoma, R. S., Richman, R., Wu, Z., Piwnica-Worms, H., & Elledge, S. J. (1997) · Science · doi:10.1126/science.277.5331.1497 · Cited by 1,320
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies
Chin, K., DeVries, S., Fridlyand, J., Spellman, P. T., Roydasgupta, R., Kuo, W.-L., Lapuk, A., Neve, R. M., Qian, Z., Ryder, T., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.009 · Cited by 1,317
Miller, L. D., Smeds, J., George, J., Vega, V. B., Vergara, L., Ploner, A., Pawitan, Y., Hall, P., Klaar, S., Liu, E. T., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506230102 · Cited by 1,268
ATR-Mediated Checkpoint Pathways Regulate Phosphorylation and Activation of Human Chk1
Zhao, H., & Piwnica-Worms, H. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.13.4129-4139.2001 · Cited by 1,091 · cited 1×
“In response to replicative stress, CHK1 is activated by ATR through phosphorylation at Ser317 and Ser345 (19).”
BackgroundChecking on DNA damage in S phase
Bartek, J., Lukas, C., & Lukas, J. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1493 · Cited by 758
Stuck in Division or Passing through
Rieder, C. L., & Maiato, H. (2004) · Developmental Cell · doi:10.1016/j.devcel.2004.09.002 · Cited by 657
The decision to enter mitosis: feedback and redundancy in the mitotic entry network
Lindqvist, A., Rodríguez-Bravo, V., & Medema, R. H. (2009) · Journal of Cell Biology · doi:10.1083/jcb.200812045 · Cited by 565
Hirai, H., Iwasawa, Y., Okada, M., Arai, T., Nishibata, T., Kobayashi, M., Kimura, T., Kaneko, N., Ohtani, J., Yamanaka, K., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0463 · Cited by 540
New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network
Dai, Y., & Grant, S. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1029 · Cited by 439
Zabludoff, S. D., Deng, C., Grondine, M. R., Sheehy, A. M., Ashwell, S., Caleb, B. L., Green, S., Haye, H. R., Horn, C. L., Janetka, J. W., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0492 · Cited by 413
Mammalian cell cycle checkpoints: signalling pathways and their organization in space and time
Lukas, J., Lukas, C., & Bartek, J. (2004) · DNA Repair · doi:10.1016/j.dnarep.2004.03.006 · Cited by 381
Centrosome-associated Chk1 prevents premature activation of cyclin-B–Cdk1 kinase
Krämer, A., Mailand, N., Lukas, C., Syljuåsen, R. G., Wilkinson, C. J., Nigg, E. A., Bartek, J., & Lukas, J. (2004) · Nature Cell Biology · doi:10.1038/ncb1165 · Cited by 342
Sorensen, C. S., & Syljuasen, R. G. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr697 · Cited by 318
Mir, S. E., De Witt Hamer, P. C., Krawczyk, P. M., Balaj, L., Claes, A., Niers, J. M., Van Tilborg, A. A. G., Zwinderman, A. H., Geerts, D., Kaspers, G. J. L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.08.011 · Cited by 294
TP53mutation status and gene expression profiles are powerful prognostic markers of breast cancer
Langerød, A., Zhao, H., Borgan, Ø., Nesland, J. M., Bukholm, I. R., Ikdahl, T., Kåresen, R., Børresen-Dale, A.-L., & Jeffrey, S. S. (2007) · Breast Cancer Research · doi:10.1186/bcr1675 · Cited by 291
Rajeshkumar, N. V., De Oliveira, E., Ottenhof, N., Watters, J., Brooks, D., Demuth, T., Shumway, S. D., Mizuarai, S., Hirai, H., Maitra, A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2580 · Cited by 274
Self-citationCollett, K., Eide, G. E., Arnes, J., Stefansson, I. M., Eide, J., Braaten, A., Aas, T., Otte, A. P., & Akslen, L. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1533 · Cited by 272
WEE1 Kinase Targeting Combined with DNA-Damaging Cancer Therapy Catalyzes Mitotic Catastrophe
De Witt Hamer, P. C., Mir, S. E., Noske, D., Van Noorden, C. J. F., & Würdinger, T. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2537 · Cited by 249
Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator.
Wang, Y., Li, J., Booher, R. N., Kraker, A. J., Lawrence, T. S., Leopold, W. R., & Sun, Y. (2001) · PubMed · Cited by 240
Hirai, H., Arai, T., Okada, M., Nishibata, T., Kobayashi, M., Sakai, N., Imagaki, K., Ohtani, J., Sakai, T., Yoshizumi, T., et al. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.9.7.11115 · Cited by 237
MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells
Bridges, K. A., Hirai, H., Buser, C. A., Brooks, C., Liu, H., Buchholz, T. A., Molkentine, J. M., Mason, K. A., & Meyn, R. E. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0650 · Cited by 237
Mechanisms of Centrosome Separation and Bipolar Spindle Assembly
Tanenbaum, M. E., & Medema, R. H. (2010) · Developmental Cell · doi:10.1016/j.devcel.2010.11.011 · Cited by 230
p21 Inhibits Thr161 Phosphorylation of Cdc2 to Enforce the G2 DNA Damage Checkpoint
Smits, V. A. J., Klompmaker, R., Vallenius, T., Rijksen, G., Mäkelä, T. P., & Medema, R. H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005437200 · Cited by 221
Wee1 controls genomic stability during replication by regulating the Mus81-Eme1 endonuclease
Domínguez-Kelly, R., Martín, Y., Koundrioukoff, S., Tanenbaum, M. E., Smits, V. A. J., Medema, R. H., Debatisse, M., & Freire, R. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201101047 · Cited by 196
Gonzalez, M. E., Li, X., Toy, K., DuPrie, M., Ventura, A. C., Banerjee, M., Ljungman, M., Merajver, S. D., & Kleer, C. G. (2009) · Oncogene · doi:10.1038/onc.2008.433 · Cited by 195
Fan, T., Jiang, S., Chung, N., Alikhan, A., Ni, C., Lee, C.-C. R., & Hornyak, T. J. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0511 · Cited by 193
Schmit, F., Korenjak, M., Mannefeld, M., Schmitt, K., Franke, C., von Eyss, B., Gagrica, S., Hanel, F., Brehm, A., & Gaubatz, S. (2007) · Cell Cycle · doi:10.4161/cc.6.15.4512 · Cited by 179
Medema, R. H., & Macůrek, L. (2012) · Oncogene · doi:10.1038/onc.2011.451 · Cited by 177
Regulators of cyclin-dependent kinases are crucial for maintaining genome integrity in S phase
Beck, H., Nähse, V., Larsen, M. S. Y., Groth, P., Clancy, T., Lees, M., Jørgensen, M., Helleday, T., Syljuåsen, R. G., & Sørensen, C. S. (2010) · Journal of Cell Biology · doi:10.1083/jcb.200905059 · Cited by 169
Knockdown of Chk1, Wee1 and Myt1 by RNA Interference Abrogates G2 Checkpoint and Induces Apoptosis
Wang, Y., Decker, S. J., & Sebolt, J. S. (2004) · Cancer Biology & Therapy · doi:10.4161/cbt.3.3.697 · Cited by 155
Functional Viability Profiles of Breast Cancer
Brough, R., Frankum, J. R., Sims, D., Mackay, A. G., Mendes‐Pereira, A. M., Bajrami, I., Costa-Cabral, S., Rafiq, R., Ahmad, A. S., Cerone, M. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0107 · Cited by 140
Self-citationAgarwal, R., Gonzalez-Angulo, A. M., Myhre, S., Carey, M. S., Lee, J., Overgaard, J., Alsner, J., Stemke‐Hale, K., Lluch, A. M., Neve, R. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3293 · Cited by 136
High cyclin B1 expression is associated with poor survival in breast cancer
Aaltonen, K., Amini, R., Heikkilä, P., Aittomäki, K., Tamminen, A., Nevanlinna, H. A., & BLOMQVIST, C. P. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604874 · Cited by 134
WEE1 inhibition sensitizes osteosarcoma to radiotherapy
PosthumaDeBoer, J., Würdinger, T., Graat, H. C. A., van Beusechem, V. W., Helder, M. N., van Royen, B. J., & Kaspers, G. J. L. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-156 · Cited by 131
CHK1 phosphorylates CDC25B during the cell cycle in the absence of DNA damage
Schmitt, E., Boutros, R., Froment, C., Monsarrat, B., Ducommun, B., & Dozier, C. (2006) · Journal of Cell Science · doi:10.1242/jcs.03200 · Cited by 121
Sarcar, B., Kahali, S., Prabhu, A. H., Shumway, S. D., Xu, Y., Demuth, T., & Chinnaiyan, P. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0469 · Cited by 121
Self-citationMurrow, L. M., Garimella, S. V., Jones, T. L., Caplen, N. J., & Lipkowitz, S. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0571-2 · Cited by 92
Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation
Davies, K. D., Cable, P. L., Garrus, J. E., Sullivan, F. X., von Carlowitz, I., Huérou, Y. L., Wallace, E. M., Woessner, R. D., & Gross, S. D. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.9.17673 · Cited by 89
B-MYB Is Required for Recovery from the DNA Damage–Induced G2 Checkpoint in p53 Mutant Cells
Mannefeld, M., Klassen, E., & Gaubatz, S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4156 · Cited by 82
Comparison of mitotic cell death by chromosome fragmentation to premature chromosome condensation
Stevens, J. B., Abdallah, B. Y., Regan, S. M., Liu, G., Bremer, S. W., Ye, C. J., & Heng, H. H. (2010) · Molecular Cytogenetics · doi:10.1186/1755-8166-3-20 · Cited by 58
Cited by
The history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
Self-citationTargeting the DNA Damage Response in Cancer
O’Connor, M. J. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.10.040 · Cited by 1,518
State-of-the-art strategies for targeting the DNA damage response in cancer
Pilié, P. G., Tang, C., Mills, G. B., & Yap, T. A. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0114-z · Cited by 1,189
Targeting DNA Repair in Cancer: Beyond PARP Inhibitors
Brown, J. S., O'Carrigan, B., Jackson, S. P., & Yap, T. A. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0860 · Cited by 618
Rational combinations of targeted cancer therapies: background, advances and challenges
Jin, H., Wang, L., & Bernards, R. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00615-z · Cited by 503
Metadata
- Authors
- Aarts, M., Sharpe, R., Garcia-Murillas, I., Gevensleben, H., Hurd, M. S., Shumway, S. D., Toniatti, C., Ashworth, A., & Turner, N. C.
- Venue
- Cancer Discovery
- Published
- 2012-06-01
- Volume
- 2
- Issue
- 6
- Pages
- 524-539
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2111222453
- Cited by
- 327
- References
- 46
- FWCI
- 7.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.